DelveInsight’s, “Brutons Tyrosine Kinase (Btk) inhibitor– Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in BTK inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Brutons Tyrosine Kinase (Btk) inhibitor Understanding
BTK inhibitor: Overview
Brutons tyrosine kinase (Btk) is a 75 kDa cytoplasmic protein tyrosine kinase that is widely expressed in hematopoietic cells. It is a 659 amino acid member of a subfamily of src-related cytoplasmic tyrosine kinases. It is a non-receptor tyrosine kinase that was initially identified as the defective protein in human X-linked agammaglobulinemia (XLA).
Function – Bruton’s tyrosine kinase (BTK) is a key component of the B-cell receptor (BCR) signaling pathway and plays an essential role in B-lymphocyte development, differentiation, and signaling. Mutations in the Btk gene lead to X-linked agammaglobulinemia (XLA) in humans.
BTK Inhibitors- Inhibition of BTK will be of therapeutic significance in the treatment of both B cell-related hematological cancers (e.g. non-Hodgkin lymphoma (NHL), B cell chronic lymphocytic leukemia (B-CLL), and autoimmune diseases (e.g. rheumatoid arthritis). BTK inhibitors has shown efficacy as therapeutic option for various B cell malignancies in clinical trials by targeting BTK. In 2013, USFDA approved first effective and selective BTK inhibitor, Ibrutinib as a breakthrough therapy.
BTK inhibitor Emerging Drugs Chapters
This segment of the BTK inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
BTK inhibitor Emerging Drugs
- Evobrutinib: Merck
- Evobrutinib (M2951) is an investigational oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor with potential antineoplastic activity. Upon administration, the drug inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. The drug is in clinical development for the treatment for multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
- Acalabrutinib: Acerta Pharma (AstraZeneca)
- Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor. Acalabrutinib binds covalently to Cys481 located at the edge of the adenosine triphosphate binding site of BTK, producing irreversible inhibition of BTK. Acalabrutinib is more selective than ibrutinib for BTK with less off-target effects. In 2017, Acalabrutinib received an accelerated USFDA approval for patients with relapsed/refractory mantle cell lymphoma. Also approved by USFDA as an effective first-line therapy for the treatment of patients with chronic lymphocytic leukemia in April 2020.
Further product details are provided in the report?
BTK inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different BTK inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on BTK inhibitor
There are approx. 30+ key companies which are developing the BTK inhibitor. The companies which have their BTK inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Merck.
- Phases
This report covers around 30+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
BTK inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
BTK inhibitor: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses BTK inhibitor therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BTK inhibitor drugs.
Report Highlights
• In August 2020, Sanofi and Principia Biopharma entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia, which specializes in Bruton’s kinase (BTK) inhibitor drugs for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion (on a fully diluted basis).
BTK inhibitor Report Insights
• BTK inhibitor Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
BTK inhibitor Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
• How many companies are developing BTK inhibitor drugs?
• How many BTK inhibitor drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for BTK inhibitor?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the BTK inhibitor therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for BTK inhibitor and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Merck
• Acerta Pharma (AstraZeneca)
• Janssen
• Pharmacyclics
• InnoCare Pharma
• TG Therapeutics
• Nurix
• Impetis Biosciences
• Loxo Oncology
• Zhejiang DTRM Biopharma
Key Products
• Evobrutinib
• Acalabrutinib
• Ibrutinib
• Orelabrutinib
• TG 1701
• NX-2127
• PNQ-617
• LOXO-305
• DTRMWXHS-12
US $
Euro €
GBP £